A phase II, randomized, multicentre study comparing 10 months vs 4 months of degarelix (Firmagon) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for biochemical recurrence following radical local therapy
The Journal of Urology Mar 16, 2018
Klotz L, et al. - Whether or not the duration of induction androgen deprivation therapy (ADT) influences the duration of the off-treatment interval and the recovery of serum testosterone (T) in men with localized prostate cancer receiving intermittent androgen deprivation therapy for biochemical recurrence following radical local therapy was determined. No difference was noted in the duration of the off-treatment interval or the rate of testosterone recovery whether or not the men received 4 or 10 months of induction ADT.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries